Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board of DirectorsScott Gottlieb, M.D.
By Erin Carron (Original source Yahoo Finance)
CHICAGO, Oct. 29, 2019 (GLOBE NEWSWIRE) — “Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an advisor to Tempus and its leadership team, leveraging his vast experience as a medical policy expert and public health advocate to support Tempus as it harnesses the power and promise of big data and artificial intelligence to personalize patient care.
Dr. Gottlieb most recently served as the 23rd Commissioner of the Food and Drug Administration (FDA), where he focused on developing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding patient choice and safety. Previously, he also served as the agency’s Deputy Commissioner for Medical and Scientific Affairs and as a Senior Advisor to the FDA Commissioner. During his time as a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services, Dr. Gottlieb worked on the implementation of the Medicare drug benefit, where he supported policy work on quality improvement and the agency’s coverage process, particularly as it related to new medical technologies.”
Click to see more